Chelsea Therapeutics (CHTP) Rocks Higher on Drug Data, Aggressive Analyst Call
Tweet
Share
E-mail
Get Alerts CHTP Hot Sheet
Price: $6.52 --0%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) are sharply higher Friday following positive trial results and comments from one analyst who thinks the stock can still rise 260 percent from here.
Today the company reported new trial data showing that its Northera was safe and effective in symptomatic neurogenic orthostatic hypotension.
Following the news Roth Capital's David Moskowitz raised his price target on the stock from $6 to $18 and sees possible FDA approval as early as Q1. He believes the drug could generate $250 million of annual sales by 2015.
Shares of Chelsea Therapeutics are up 17 percent to $4.92 in early trading Friday.
Today the company reported new trial data showing that its Northera was safe and effective in symptomatic neurogenic orthostatic hypotension.
Following the news Roth Capital's David Moskowitz raised his price target on the stock from $6 to $18 and sees possible FDA approval as early as Q1. He believes the drug could generate $250 million of annual sales by 2015.
Shares of Chelsea Therapeutics are up 17 percent to $4.92 in early trading Friday.
Create E-mail Alert Related Categories
Analyst Comments, FDA, Hot CommentsRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
